open access

Vol 57, No 2 (2019)
ORIGINAL PAPERS
Published online: 2019-06-14
Submitted: 2019-05-17
Accepted: 2019-05-21
Get Citation

WNT5A gene and protein expression in endometrial cancer

Tomasz Wasniewski, Jacek Kiezun, Bartlomiej E. Krazinski, Anna E. Kowalczyk, Blazej Szostak, Piotr M. Wierzbicki, Jolanta Kiewisz
DOI: 10.5603/FHC.a2019.0010
·
Pubmed: 31198984
·
Folia Histochem Cytobiol 2019;57(2):84-93.

open access

Vol 57, No 2 (2019)
ORIGINAL PAPERS
Published online: 2019-06-14
Submitted: 2019-05-17
Accepted: 2019-05-21

Abstract

Introduction. WNT5A (Wnt family member 5A) belongs to the WNT family of secreted signaling glycoproteins that play essential role in developmental, physiological and pathological processes. WNT5A was shown to take part in carcinogenesis process playing both oncogenic and suppressor functions in various types of human malignancies. This study aimed to assess the expression of the WNT5A gene at the mRNA and protein levels in the specimens derived from endometrial cancer (EC) or unchanged control endometrium. The associations between the WNT5A expression levels and clinicopathological characteristics and survival of EC patients were evaluated.

Materials and methods. Total RNA was isolated in order to assess the relative amounts of WNT5A mRNA by quantitative polymerase chain reaction (QPCR) in samples of unchanged endometrial control (n = 8) and tumor samples of EC patients (n = 28). Immunohistochemistry (IHC) was used to determine the presence of WNT5A protein in the sections of formalin-fixed, paraffin-embedded tissue specimens derived from unchanged endome­trial controls (n = 6) and EC tumors (n = 19). Significance of differences in WNT5A expression levels between the studied groups of EC patients and correlations between the WNT5A and demographic data, pathological features, hematological parameters and overall survival of the patients were evaluated by statistical analysis.

Results. The level of WNT5A mRNA was decreased in EC in comparison to unchanged endometrium. WNT5A expression was associated with primary tumor invasion status exhibiting reduced level of transcripts in EC that involved organs beyond the uterus when compared to the uterus-confined cancers. WNT5A immunoreactivity was visualized in the cytoplasm and nuclei of EC cells as well as in the luminal and glandular epithelial cells of unchanged endometrium. WNT5A mRNA expression levels correlated negatively with cytoplasmic, and positively with nuclear immunoreactivity of the WNT5A protein in the EC cells. In addition, the relationships between blood leucocyte count (in particular granulocytes and lymphocytes) of patients with EC and their WNT5A mRNA and protein expression levels were established. A positive correlation between the nuclear immunoexpression of WNT5A protein in the cancer cells in cell nuclei and mean platelet volume in blood was also found.

Conclusions. The results of the first study of WNT5A expression at the transcript and protein levels indicate that it could be considered as a potential marker of molecular changes that take place during EC development.

Abstract

Introduction. WNT5A (Wnt family member 5A) belongs to the WNT family of secreted signaling glycoproteins that play essential role in developmental, physiological and pathological processes. WNT5A was shown to take part in carcinogenesis process playing both oncogenic and suppressor functions in various types of human malignancies. This study aimed to assess the expression of the WNT5A gene at the mRNA and protein levels in the specimens derived from endometrial cancer (EC) or unchanged control endometrium. The associations between the WNT5A expression levels and clinicopathological characteristics and survival of EC patients were evaluated.

Materials and methods. Total RNA was isolated in order to assess the relative amounts of WNT5A mRNA by quantitative polymerase chain reaction (QPCR) in samples of unchanged endometrial control (n = 8) and tumor samples of EC patients (n = 28). Immunohistochemistry (IHC) was used to determine the presence of WNT5A protein in the sections of formalin-fixed, paraffin-embedded tissue specimens derived from unchanged endome­trial controls (n = 6) and EC tumors (n = 19). Significance of differences in WNT5A expression levels between the studied groups of EC patients and correlations between the WNT5A and demographic data, pathological features, hematological parameters and overall survival of the patients were evaluated by statistical analysis.

Results. The level of WNT5A mRNA was decreased in EC in comparison to unchanged endometrium. WNT5A expression was associated with primary tumor invasion status exhibiting reduced level of transcripts in EC that involved organs beyond the uterus when compared to the uterus-confined cancers. WNT5A immunoreactivity was visualized in the cytoplasm and nuclei of EC cells as well as in the luminal and glandular epithelial cells of unchanged endometrium. WNT5A mRNA expression levels correlated negatively with cytoplasmic, and positively with nuclear immunoreactivity of the WNT5A protein in the EC cells. In addition, the relationships between blood leucocyte count (in particular granulocytes and lymphocytes) of patients with EC and their WNT5A mRNA and protein expression levels were established. A positive correlation between the nuclear immunoexpression of WNT5A protein in the cancer cells in cell nuclei and mean platelet volume in blood was also found.

Conclusions. The results of the first study of WNT5A expression at the transcript and protein levels indicate that it could be considered as a potential marker of molecular changes that take place during EC development.

Get Citation

Keywords

WNT5A expression; endometrial cancer; platelets volume; QPCR; IHC

About this article
Title

WNT5A gene and protein expression in endometrial cancer

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 57, No 2 (2019)

Pages

84-93

Published online

2019-06-14

DOI

10.5603/FHC.a2019.0010

Pubmed

31198984

Bibliographic record

Folia Histochem Cytobiol 2019;57(2):84-93.

Keywords

WNT5A expression
endometrial cancer
platelets volume
QPCR
IHC

Authors

Tomasz Wasniewski
Jacek Kiezun
Bartlomiej E. Krazinski
Anna E. Kowalczyk
Blazej Szostak
Piotr M. Wierzbicki
Jolanta Kiewisz

References (30)
  1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359–E386.
  2. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11:1531–43. PMID. ; 12496040.
  3. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371(9612): 569–578.
  4. Siegel RL, Fedewa SA, Miller KD, et al. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1): 5–29.
  5. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15(1): 10–17.
  6. Ryan AJ, Susil B, Jobling TW, et al. Endometrial cancer. Cell Tissue Res. 2005; 322(1): 53–61.
  7. Santacana M, Maiques O, Valls J, et al. A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry. Hum Pathol. 2014; 45(12): 2394–2403.
  8. Coenegrachts L, Garcia-Dios DA, Depreeuw J, et al. Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas. Virchows Arch. 2015; 466(4): 415–422.
  9. Hoang LN, McConechy MK, Köbel M, et al. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am J Surg Pathol. 2013; 37(9): 1421–1432.
  10. Krejczy K, Cymbaluk-Płoska A, Kwiatkowski S, et al. Molecular characteristics of endometrial cancer and their potential effect on clinical management. Current Gynecologic Oncology. 2019; 16(4): 245–250.
  11. Nusse R, Clevers H. Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell. 2017; 169(6): 985–999.
  12. Yamaguchi TP, Bradley A, McMahon AP, et al. A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. Development. 1999; 126(6): 1211–1223.
  13. Bauer M, Bénard J, Gaasterland T, et al. WNT5A encodes two isoforms with distinct functions in cancers. PLoS One. 2013; 8(11): e80526.
  14. McDonald SL, Silver A. The opposing roles of Wnt-5a in cancer. Br J Cancer. 2009; 101(2): 209–214.
  15. Asem MS, Buechler S, Wates RB, et al. Wnt5a Signaling in Cancer. Cancers (Basel). 2016; 8(9).
  16. Bui TD, Zhang L, Rees MC, et al. Expression and hormone regulation of Wnt2, 3, 4, 5a, 7a, 7b and 10b in normal human endometrium and endometrial carcinoma. Br J Cancer. 1997; 75(8): 1131–1136.
  17. Greene FL, Page DL, Fleming ID, et al. Gynecological sites. In: American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th edition. Springer, New York, NY. ; 2002: 241–300.
  18. Petru E, Lück HJ, Stuart G, et al. Gynecologic Cancer Intergroup (GCIG). Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system. Eur J Obstet Gynecol Reprod Biol. 2009; 143(2): 69–74.
  19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4): 402–408.
  20. Romani C, Calza S, Todeschini P, et al. Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues. PLoS One. 2014; 9(12): e113781.
  21. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987; 8(3): 138–140.
  22. Bitler BG, Nicodemus JP, Li H, et al. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res. 2011; 71(19): 6184–6194.
  23. Peng C, Zhang X, Yu H, et al. Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer. Int J Gynecol Cancer. 2011; 21(2): 280–288.
  24. Lin Li, Liu Y, Zhao W, et al. Wnt5A expression is associated with the tumor metastasis and clinical survival in cervical cancer. Int J Clin Exp Pathol. 2014; 7(9): 6072–6078.
  25. Farrell CM, O'Leary NA, Harte RA, et al. Current status and new features of the Consensus Coding Sequence database. Nucleic Acids Res. 2014; 42(Database issue): D865–D872.
  26. Kosugi S, Hasebe M, Tomita M, et al. Systematic identification of cell cycle-dependent yeast nucleocytoplasmic shuttling proteins by prediction of composite motifs. Proc Natl Acad Sci U S A. 2009; 106(25): 10171–10176.
  27. Cummings M, Merone L, Keeble C, et al. Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival. Br J Cancer. 2015; 113(2): 311–320.
  28. Arabzadeh S, Hossein G, Zarnani AH. Wnt5A exerts immunomodulatory activity in the human ovarian cancer cell line SKOV-3. Cell Biol Int. 2016; 40(2): 177–187.
  29. Holtzhausen A, Zhao F, Evans KS, et al. Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. Cancer Immunol Res. 2015; 3(9): 1082–1095.
  30. Kim SY, Kim S, Yun-Choi HS, et al. Wnt5a potentiates U46619-induced platelet aggregation via the PI3K/Akt pathway. Mol Cells. 2011; 32(4): 333–336.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl